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HLA-B*1502 Screening and Toxic Effects of Carbamazepine
To the Editor: Chen et al. (March 24 issue)1 re-
port the absence of the Stevens–Johnson syn-
drome and its related disease, toxic epidermal ne-
crolysis (SJS–TEN), in subjects who were screened 
for the HLA-B*1502 allele and were advised not 
to take carbamazepine if they carried the allele. 
Case–control studies involving subjects of Han 
Chinese and Thai origin have also shown an asso-
ciation between SJS–TEN and the receipt of pheny-
toin,  lamotrigine,  and  oxcarbazepine  among 
HLA-B*1502 carriers.2-4 The Food and Drug Ad-
ministration has stated that “healthcare providers 
should consider avoiding phenytoin as alterna-
tives for CBZ [carbamazepine] in patients who test 
positive for HLA-B*1502.”5 Chen et al. state that 
lamotrigine and oxcarbazepine were among the 
alternative medications offered to HLA-B*1502 
carriers and did not indicate whether the inves-
tigators or treating physicians warned patients 
not to take phenytoin. The increasing use of 
HLA-B*1502 screening to prevent carbamazepine-
induced SJS–TEN will lead to the replacement of 
this  drug  with  other  anticonvulsants  among 
HLA-B*1502 carriers. Given the availability of 
other elective therapeutic choices, it may be pru-
dent to advise HLA-B*1502 carriers to avoid not 
only carbamazepine but also other structurally 
related anticonvulsants, such as phenytoin, oxcar-
bazepine, and possibly lamotrigine.
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To the Editor: Chen et al. report that SJS–TEN 
did not develop in subjects testing negative for 
HLA-B*1502 who received carbamazepine. After 
genotyping HLA-B in 11 patients who had carba-
mazepine-induced  SJS–TEN  and  who  were  of 
southern Han Chinese origin, we observed that 
3 of these patients were negative for HLA-B*1502. 
Rather, they carried HLA-B*1511/1511, 5401/5401, 
and 4001/4601. Some early studies1 suggested 
that Han Chinese persons with carbamazepine-
induced SJS–TEN who lived in Taiwan, Hong Kong, 
or some Southeast Asian countries were almost 
all  HLA-B*1502  carriers.  More  recent  studies 
have reported more instances of SJS–TEN among 
persons who were negative for HLA-B*1502.2 
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Since it has been reported that European and 
Japanese  patients  with  carbamazepine-induced 
SJS–TEN were negative for HLA-B*1502,3 we sug-
gest that the risk of this disorder is not nil in 
such patients and that physicians should be vigi-
lant about the possibility of this disorder in pa-
tients  receiving  carbamazepine,  regardless  of 
their HLA-B genotype.
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The authors reply: We agree with Phillips and 
Mallal that it is important to advise HLA-B*1502 
carriers to avoid not only carbamazepine but also 
other structurally related anticonvulsants, such 
as phenytoin, oxcarbazepine, and lamotrigine. In 
a recent study,1 we found that when these drugs 
were  associated  with  SJS–TEN,  the  patients 
shared a common risk allele (i.e., HLA-B*1502), 
so the drugs may act on a similar pathogenic 
mechanism. We do not exclude the possibility of 
the pathogenic contribution of other alleles to 
carbamazepine-induced SJS–TEN, such as those 
described by Liao et al. However, to test whether 
associations with such alleles are significant re-
quires a case–control study comparing the preva-
lence of these alleles in persons with carbamaze-
pine-induced  SJS–TEN  and  their  prevalence  in 
persons tolerant of carbamazepine.
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